FATZO serves as platform for non-alcoholic fatty liver disease

Drug discovery company, Crown Bioscience, has made progress in developing a model of non-alcoholic fatty liver disease (NAFLD). 

The new NAFLD model was created by Preclinomics, a Crown Bioscience company, using its proprietary FATZO model for obesity and Type 2 diabetes. The FATZO model is a spontaneously hyperglycemic model and serves as an excellent translational platform for developing models of NAFLD.

“The new model complements our NHP model of NAFLD and non-alcoholic steatohepatitis (NASH), creating a continuum of in vivo platforms that enables us to provide our clients with end-to-end preclinical support for their CVMD research,” said Jim Wang, senior vice president of cardiovascular and metabolic disease research at CrownBio. “It can be used as a translational tool to study novel compounds in late stage drug discovery.”

“Presently there are no approved therapies for NASH,” said Van Jackson, general manager and CSO at Preclinomics. “In its most severe form, NASH disease can lead to liver cancer and the need for transplantation. We are hopeful this new research model can be used as a translational model for NASH and lead to new avenues for treatment and recovery.”